Jump to main content
Jump to site search
SCHEDULED MAINTENANCE Close the message box

Maintenance work is planned for Monday 16 August 2021 from 07:00 to 23:59 (BST).

Website performance may be temporarily affected and you may not be able to access some PDFs or images. If this does happen, refreshing your web browser should resolve the issue. We apologise for any inconvenience this might cause and thank you for your patience.


All chapters

CHAPTER 13

Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugs

Adherence to an active antiviral regimen, driven a by a low pill burden, convenient dosing schedule, and favorable tolerability and safety profiles, plays a critical role in the successful treatment of chronic viral infection and the prevention of resistance development. Cytochrome P450 3A (CYP3A) inhibitors ritonavir and cobicistat significantly improve the pharmacokinetic profiles of therapeutic drugs, such as the HIV protease inhibitor atazanavir and integrase inhibitor elvitegravir that are metabolized by the CYP3A, resulting in reduced pill burn, decreased dosing frequency and an improved safety profile. Both ritonavir and cobicistat have contributed to the simplification of dosing regimens and improved adherence, ensuring the successful long‐term management of HIV infection.

Publication details


Print publication date
10 Jun 2013
Copyright year
2013
Print ISBN
978-1-84973-657-2
PDF eISBN
978-1-84973-781-4
From the book series:
Drug Discovery